Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ultragenyx Pharmaceutical (RARE) Equity Average: 2016-2025

Historic Equity Average for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $80.2 million.

  • Ultragenyx Pharmaceutical's Equity Average fell 79.41% to $80.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.2 million, marking a year-over-year decrease of 79.41%. This contributed to the annual value of $265.4 million for FY2024, which is 15.48% down from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Equity Average is $80.2 million, which was down 45.71% from $147.8 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Equity Average ranged from a high of $1.1 billion in Q1 2021 and a low of $80.2 million during Q3 2025.
  • Moreover, its 3-year median value for Equity Average was $199.8 million (2025), whereas its average is $209.8 million.
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's Equity Average tumbled by 85.98% in 2023, and later soared by 384.77% in 2024.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Equity Average (Quarterly) stood at $928.1 million in 2021, then crashed by 55.75% to $410.7 million in 2022, then slumped by 62.61% to $153.6 million in 2023, then spiked by 96.05% to $301.1 million in 2024, then plummeted by 79.41% to $80.2 million in 2025.
  • Its Equity Average was $80.2 million in Q3 2025, compared to $147.8 million in Q2 2025 and $199.8 million in Q1 2025.